Sheffield event on echo/imaging in pulmonary hypertension, co-organised and fully funded by Janssen

This content is published as part of a paid advertising agreement.

Dr Thanos Charalampopoulos and Janssen are delighted to announce that the 4th Sheffield educational meeting on echocardiography/imaging in pulmonary hypertension (PH) will be taking place on 8th and 22nd October 2021. 

Using the experience gained from three successful meetings and past delegates’ feedback, this year Janssen is organising two half-day virtual meetings dedicated to the assessment of patients with PH with a special focus on echocardiography/imaging. These meetings are suitable for cardiac physiologists as well as clinicians such as cardiologists, respiratory physicians, and rheumatologists.

The delay in diagnosis for PH can be >2 years, which can significantly affect a patient’s risk of mortality and increase the chance of the patient presenting with severe disease1. Therefore, earlier diagnosis can have a significant impact on a patient’s well-being and survival1.

Our first aim of these meetings is to help delegates to better recognise PH through clinical signs and imaging, helping to increase awareness of the disease, earlier diagnosis and facilitate appropriate referrals to an expert PH centre. Imaging plays a paramount role in the diagnosis, risk stratification and assessment of response to therapies in patients with PH. These meetings will also help to familiarise attendees with all aspects of echocardiography, from 2D assessment to newer techniques like 3D and speckle tracking, as well as with other imaging modalities essential in PH, like CT and cardiac MRI.

In addition, the rest of the faculty and I are planning to cover diagnostic tests of PH like right heart catheterisation, which remains the gold standard for the diagnosis and phenotyping of the different types of PH. For many years, the right ventricle had been the ‘forgotten ventricle’ but now it is widely recognised for its pathologies that can be responsible for patients’ symptoms and poor prognosis. In PH, it is the right heart that is mostly affected by the disease; therefore, we will be concentrating on its physiology and assessment during these meetings.

Whether you are a cardiac physiologist or a clinician reading echocardiography reports, these meetings will cover everything from the different measures of the size and function of the right heart and right-side valves, through to interpretation of echocardiography reports’, parameters to look out for and what caveats may affect their accuracy.

I am delighted to announce that I will be joined by international distinguished experts in the fields of PH and cardiac imaging to deliver the talks of these meetings. I hope you will be able to join us!

Dr Thanos Charalampopoulos, Consultant Cardiologist with special interest in PH

Register here

For more information on PAH, click here


  1. Weatherald J & Humbert M. Respirology 2020;25:790–792


CP-255045 | August 2021

This content is published as part of a paid advertising agreement.